Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and…
Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes
LEHI, Utah, Oct. 23, 2025 /PRNewswire/ --Â Halia Therapeutics, Inc., a clinical-stage biopharmaceutical…
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical…
Sameer Kanodia, Managing Director and CEO, Lumina Datamatics, and Vice Chairman and CEO, TNQTech, honored with ‘India’s Top 50 CEOs, MDs, and Founders’ Recognition by the Great Manager Institute for 2025
MUMBAI, India, June 3, 2025 /PRNewswire/ -- Sameer Kanodia, Managing Director and…